Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Left Ventricular Dysfunction

4

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Angiotensin-converting enzyme

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1981

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

ChEMBL

4

EPA CompTox

4

EVMPD

4

FDA UNII

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ACE INHIBITORS, COMBINATIONS

1

ACE INHIBITORS, PLAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

ACE inhibitors and diuretics

1

ACE inhibitors, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CAPTOPRIL

9G64RSX1XD

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Left Ventricular Dysfunction

Diabetic Nephropathy

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to a...

nd inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

ALACEPRIL

X39TL7JDPF

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Left Ventricular Dysfunction

Diabetic Nephropathy

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to a...

nd inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

MOVELTIPRIL

LQI0441316

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Left Ventricular Dysfunction

Diabetic Nephropathy

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to a...

nd inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

PIVOPRIL

3V6I5962EM

Export Data
Search for Structure

Status:

US Approved Rx (1998)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Angiotensin-converting enzyme

Conditions:

Left Ventricular Dysfunction

Diabetic Nephropathy

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to a...

nd inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1